September 14, 2014 10:07 PM ET

Biotechnology

Company Overview of Cellectis Bioresearch SAS

Company Overview

Cellectis bioresearch SAS focuses on the development of meganuclease-based targeted integration products for the generation of stable and isogenic cell lines for the drug discovery, gene function, and protein production markets. It offers genome customization toolkits, which include reagents and protocols that enable precise modifications of DNA sequences in a targeted genome, including a cell line, a primary or stem cell, or a whole organism; meganucleases, which are sequence-specific endonucleases; cGPS, a cellular genome positioning system; and cGPS custom targeted integration kits, which enable the engineering of cell lines for drug discovery, protein production, and gene function studie...

8 rue de la Croix Jarry

Paris,  75013

France

Founded in 2008

Phone:

33 1 81 69 16 01

Fax:

33 1 81 69 16 07

Key Executives for Cellectis Bioresearch SAS

Chief Operating Officer
Compensation as of Fiscal Year 2014.

Cellectis Bioresearch SAS Key Developments

Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays

Axxam and Cellectis bioresearch have started a collaboration to offer to the Life Science industry an extensive range of integrated discovery services based on genomic engineering technologies. Under the joint offering, clients will be provided with a one-stop-shop approach for the generation of cell-based assays through genomic engineering. Genes of interest will be modified using Cellectis bioresearch's proprietary genome engineering technologies, after which functional cellular assays will be developed using Axxam's expertise and technologies for cell line generation. Both the required gene modification and the resulting functionality change will be experimentally demonstrated. Finally, validated assays for screening and profiling experiments will be provided to the client. With the currently available genome engineering technologies virtually any gene, at any position, in any cell type can be addressed for a wide range of applications such as knock-in insertions, knock-out deletions, reporter cell line generations and others.

Cellectis Bioresearch Launches Compact TALEN(TM)

Cellectis bioresearch announced the launch of a monomeric Compact TALEN(TM), that allows efficient transfection and genome editing in sensitive cells. Transfection of sensitive cells such as primary cells, plant cells and iPS cells is the major limitation for efficient genome editing. To breakdown this barrier, Cellectis scientists have developed a monomeric TALEN(TM), distributed under the name Compact TALEN(TM). In contrast to Custom TALEN(TM), the monomeric Compact TALEN(TM) requires the expression of only one DNA or RNA molecule to be active. This exquisite property, not only ease DNA/RNA cell transfection but offers a tremendous advantage to scientist who have to use viral shuttles for vectorization. This technology greatly simplifies the design and synthesis as well as the therapeutic delivery of nucleases. This new product based on Cellectis' proprietary TAL effector nuclease technology makes it possible to target specific DNA segments using just a single molecule.

Cellectis bioresearch SAS Launches VizuCELL Cell Lines for Live Cell Imaging

Cellectis bioresearch SAS announced the launch of VizuCELL cell lines, a tool for live cell imaging. As live cell imaging has become a requisite analytical tool in most cell biology laboratories, Cellectis bioresearch has developed VizuCELL cell lines for biomedical research and cell biology. VizuCELL cell lines offer an exceptional tool to study temporal and spatial dynamic processes in living cells in order to get critical insights into morphological changes and physiological events in real time. VizuCELL are generated by utilizing its proprietary TALEN(TM) technology to tag endogenous genes with a fluorescent signal controlled by the endogenous promoter. The VizuCELL product line comprises the most popular cell lines in imaging (HeLa and U-2 OS), which are large cells growing in monolayers, therefore enabling unambiguously visualization of cell organelles and the cytoskeleton. VizuCELL is suitable for non-invasive long-term monitoring. Due to stable endogenous protein expression the obtained information mirrors models closer to real life. VizuCELL simplifies the experimental with ready-to go imaging for a faster and cost effective workflow.

Similar Private Companies By Industry

Company Name Region
Laboratoire CL TECH Europe
Bristol-Myers Squibb Europe GIE Europe
IVF Biotech Robotics Europe
MabLife SAS Europe
PicoTwist Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
July 29, 2014
Cellectis AB
Merger/Acquisition
January 7, 2014
Ectycell SASU
Private Placement
December 30, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cellectis Bioresearch SAS, please visit www.cellectis-bioresearch.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.